In a note to the NZX yesterday, the cancer diagnostics company said an update offered no explanation but followed representations by Pacific Edge to Novitas, its parent company GuideWell, the Centers for Medicare and Medicaid Services (CMS), the US Department of Health and Human Services Office of the General Counsel (OGC), and incoming political leadership to have the local coverage determination revised or withdrawn.
Earlier this month, Medicare administrative contractor Novitas, which has jurisdiction for Pacific Edge’s US laboratory, denied coverage for the cost of its Cxbladder tests in the US.
At that time, Pacific Edge said it "cannot believe" Novitas did not review its most recent evidence for its Cxbladder tests, after committing to do so in writing, and it was considering a legal challenge.
The decision, which would end reimbursement by Medicare for its Cxbladder Triage, Detect and Monitor lines, was scheduled to take effect from February 23 but the extension meant it was now April 24.
Pacific Edge said it would update shareholders as more information came to hand.
